Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Xilio Therapeutics Inc <XLO.OQ> expected to post a loss of 92 cents a share - Earnings Preview
Xilio Therapeutics Inc XLO.OQ XLO.O is expected to show a fall in quarterly revenue when it reports results on August 12 for the period ending September 30 2026
The Waltham Massachusetts-based company is expected to report a 69.9% decrease in revenue to $5.74 million from $19.07 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Xilio Therapeutics Inc is for a loss of 92 cents per share.
The one available analyst rating on the shares is "strong buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Xilio Therapeutics Inc is $20.00, about 117.9% above its last closing price of $9.18
This summary was machine generated August 12 at 12:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Xilio Therapeutics
See all newsXilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Xilio Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Xilio Therapeutics Reports Second Quarter 2026 Financial Results And Provides Pipeline And Business Updates
U.S. STOCKS ON THE MOVE-Palantir, AeroVironment, Valvoline
U.S. STOCKS ON THE MOVE-Medtronic, AeroVironment, Tesla